Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROSPER: MRI Evaluation of Inner Ear in Meniere's Disease
NCT02530931Phase 4Terminated
- Sponsor
- CHU Grenoble Alpes
- Start
- Mar 2016
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of gadoterate meglumine in Meniere's disease (MD), sponsored by CHU Grenoble Alpes. Primary endpoint: Gadolinium enhancement in inner ear structures at 4 hours. Started Mar 2016; status: terminated.
02
Drugs
gadoterate meglumine
03
Conditions
Meniere's disease (MD)
Beyond the preview
Go deeper on NCT02530931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02530931.